Keep mRNA Flu Shots Off the Market

On June 18, the federal Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted to approve Moderna’s mFlusiva mRNA flu vaccine for people over 50 despite serious concerns from both scientists and the public about the safety and efficacy of the product. If approved, mFlusiva would be the first mRNA seasonal flu shot licensed in the US. 

VRBPAC’s approval follows the rejection in February of mFlusiva by the FDA’s Center for Biologics Evaluation and Research (CBER). Since the rejection letter was issued, both FDA Commissioner Marty Makary and CBER Director Vinay Prasad have left the administration.

The only other mRNA vaccine on the market is the COVID shot which has an alarming safety track record including 39,166 deaths among 1.7 million adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). 

The COVID crisis and its continuing aftermath have brought enlightenment to a rapidly growing number of Americans on the crucial need for independent research and transparency when it comes to government recommendations, especially those involving vaccines. This is what the American people voted for in 2024.

We also voted for full independent investigations into the enormous safety and efficacy issues with mRNA technology specifically, and the profound corruption that was essential to bringing COVID shots to the market.

VRBAC’s recommendations are advisory but are usually accepted. A final decision is expected by August 5.

Use the form below to contact President Trump along with your Senators and Congressional Representative and urge them to ensure that this highly questionable product is not brought to market until independent and thorough scientific investigation can prove its safety and efficacy.